Leila Godfrey
PhD
Postdoctoral Immunologist
- Post-doctoral scientist working on The Oxford Vaccine Centre’s COVID-19 vaccine trial, at The Jenner Institute
The Lambe Group
Working in the ChAdOx1 nCoV-19 trial team, I contribute to measuring the magnitude, longevity and phenotype of the T cell response to the SARS-CoV-2 vaccine. Lead for the variants trial, I am also collaborating with the Dong Group to explore in depth the vaccine response to challenge by emerging variants of concern.
Before The Jenner Institute, I worked with Professor John Todd at the Diabetes and Inflammation Laboratory (DIL) in the Wellcome Centre for Human Genetics. Here, I helped to develop a novel single cell sequencing technology which combines mRNA and protein quantitation. This new assay has now been used to explore regulatory T cell populations in autoimmune disease. I also performed flow cytometric phenotyping analyses for biomarker identification in clinical trial samples from patients with type 1 diabetes, with specialist training in the purification of specific lymphoid populations by flow cytometric sorting (BD FACSAria Fusion).
Prior to DIL, I worked for 2 years in Analytical Development at Immunocore, a Biotech with clinical stage T cell receptor therapies. My Doctoral training under Professor Margaret Callan at Imperial College London, studied the role of Natural Killer Cells in dysfunctional inflammation.
Recent publications
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Journal article
Voysey M. et al, (2023), Clinical and Experimental Immunology
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Journal article
Mentzer AJ. et al, (2023), Nature Medicine, 29, 147 - 157
-
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination
Journal article
Foster WS. et al, (2022), Cell Reports Medicine, 3, 100845 - 100845
-
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
Journal article
Zhang J-Y. et al, (2022), Nature Communications, 13
-
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Journal article
Fidler S. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America